CSPC Baike (Shandong) Biopharmaceutical
CompanyChina
CSPC Baike (Shandong) Biopharmaceutical develops one asset, approved (dulaglutide in cardiovascular disease). Mostly protein or enzyme acting on Insulin/IGF-1 signalling and GLP1R; based in China.
- 1
- Asset
- Furthest stage
- Approved
- 3
- Trials
- 2
- Signals
Pipeline
1GLP-1 receptor agonist that enhances glucose-dependent insulin secretion.
Approved, Protein or enzyme, Insulin/IGF-1 signalling, GLP1R, cardiovascular disease, cardiovascular events
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials3
- Signals20
- Similar companies6